Cortendo's Pipeline

Based on Cortendo's commitment to novel treatments in Metabolic Syndrome and Diabetes, the Company's strategy includes expansion of its leadership position in field with a de-risked Phase IIb lead program for type 2 diabetes (COR003) through development of a novel NCE program to identify a selective Cortisol inhibitor with an improved therapeutic profile (COR004) and actively seeking novel and synergistic programs to existing pipeline, thereby enhancing the Company's competitive position.